Compare JOB & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JOB | TXMD |
|---|---|---|
| Founded | 1893 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.9M | 24.4M |
| IPO Year | 2021 | 2012 |
| Metric | JOB | TXMD |
|---|---|---|
| Price | $0.25 | $2.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 313.3K | 27.5K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.68 |
| EPS | N/A | ★ 0.02 |
| Revenue | ★ $96,504,000.00 | $1,761,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $111.00 |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $0.17 | $0.99 |
| 52 Week High | $0.28 | $2.95 |
| Indicator | JOB | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 70.06 | 64.65 |
| Support Level | $0.22 | $2.07 |
| Resistance Level | $0.27 | $2.26 |
| Average True Range (ATR) | 0.01 | 0.05 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 91.20 | 68.75 |
GEE Group Inc is a provider of specialized staffing solutions across the United States. The company's operating segment includes Industrial Staffing Services and Professional Staffing Services. It generates maximum revenue from the Professional Staffing Services segment. The company provides the following services, direct hire placement services, temporary professional services staffing in the fields of information technology, accounting, finance and office, engineering, and medical, and temporary light industrial staffing.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.